LGND News and Press, Ligand Pharmaceuticals Incorporated From 10/15/19

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company's Board of Directors, effective today. Ms. Boyce currently serves as President and CEO of Avidity Biosciences, Inc., a private...

Editors' Note: This is the transcript version of the podcast we published yesterday on Ligand Pharmaceuticals ( LGND ). We hope you enjoy it. Introduction Daniel Shvartsman: This week on Behind The Idea we talk about Ligand Pharmaceuticals, ticker symbol, LGND. The company and the S...

by Daniel Shvartsman Listen to or subscribe to Behind the Idea on these podcast platforms: iTunes/Apple Podcasts Spotify Stitcher Libsyn Ligand Pharmaceuticals has been both a strong performer over the past decade and a target of short sellers for so...

Best Pick performance overview Source: Bloomberg and author’s calculations The table above sets out my 2019 Best Picks and their absolute and relative (to the iShares Russell 2000 ETF ( IWM )) performance. I find it useful to track not only my Best Picks but two other companies I...

Business Overview Ligand Pharmaceuticals ( LGND ) is a biopharmaceutical company concentrating on platforms and technologies that help pharmaceutical companies develop medicines. Ligand tends to focus on discovery and early-stage drug development while effectively outsourcing the late-stage ...

COLUMBUS, Ohio, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, today announced the enrollment and dosing of...

The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with this Read more ...

Market Assessment In the last 12 months, the price of Ligand ( LGND ) stock has depreciated from a high of ~$252 on September 6th, 2018, to today’s price of ~$88. As a small market cap ($1.7B) creating and/or acquiring technologies to develop innovative therapeutics, LGND has a uniq...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the H.C. Wainwright 21 st Annual Global Investment Conference in New York City. Presentation takes place on Tuesday, September 10, 2019 at 8:45 a.m. Eastern Time. John Higgins, CEO,...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, the U.S., and throughout the world, annou...